Overbought Stocks
AXGN appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
AXOGEN INC (AXGN) Stock Price & Overview
NASDAQ:AXGN • US05463X1063
Current stock price
41.99 USD
+2.6 (+6.6%)
At close:
42.0559 USD
+0.07 (+0.16%)
After Hours:
The current stock price of AXGN is 41.99 USD. Today AXGN is up by 6.6%. In the past month the price increased by 34.07%. In the past year, price increased by 145.13%.
AXGN Key Statistics
52-Week Range9.215 - 45.83
Current AXGN stock price positioned within its 52-week range.
1-Month Range30.42 - 45.83
Current AXGN stock price positioned within its 1-month range.
- Market Cap
- 2.179B
- P/E
- 144.79
- Fwd P/E
- 75.54
- EPS (TTM)
- 0.29
- Dividend Yield
- N/A
AXGN Stock Performance
Today
+6.6%
1 Week
+17.00%
1 Month
+34.07%
3 Months
+20.49%
Longer-term
6 Months +88.97%
1 Year +145.13%
2 Years +555.07%
3 Years +365.52%
5 Years +124.31%
10 Years +621.48%
AXGN Stock Chart
AXGN Stock Screens
AXGN currently appears in the following ChartMill screener lists.
AXGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AXGN. When comparing the yearly performance of all stocks, AXGN is one of the better performing stocks in the market, outperforming 95.02% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
AXGN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AXGN. While AXGN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AXGN Earnings
On April 28, 2026 AXGN reported an EPS of 0.07 and a revenue of 61.46M. The company missed EPS expectations (-28.62% surprise) and beat revenue expectations (4.34% surprise).
Next Earnings DateN/A
Last Earnings DateApr 28, 2026
PeriodQ1 / 2026
EPS Reported$0.07
Revenue Reported61.46M
EPS Surprise -28.62%
Revenue Surprise 4.34%
AXGN Forecast & Estimates
16 analysts have analysed AXGN and the average price target is 41.62 USD. This implies a price decrease of -0.89% is expected in the next year compared to the current price of 41.99.
For the next year, analysts expect an EPS growth of 91.69% and a revenue growth 18.67% for AXGN
Analysts
Analysts83.75
Price Target41.62 (-0.88%)
EPS Next Y91.69%
Revenue Next Year18.67%
AXGN Groups
Sector & Classification
AXGN Financial Highlights
Over the last trailing twelve months AXGN reported a non-GAAP Earnings per Share(EPS) of 0.29. The EPS increased by 123.08% compared to the year before.
Income Statements
Revenue(TTM)225.21M
Net Income(TTM)-15.70M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.08% | ||
| ROE | -12.19% | ||
| Debt/Equity | 0.38 |
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%21.25%
EPS 1Y (TTM)123.08%
Revenue 1Y (TTM)20.21%
AXGN Ownership
Ownership
Inst Owners83.37%
Shares51.90M
Float50.00M
Ins Owners1.38%
Short Float %7.46%
Short Ratio3.55
AXGN Latest News, Press Relases and Analysis
13 hours ago - By: Chartmill
AXGN Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 40.01 | 167.282B | ||
| ABT | ABBOTT LABORATORIES | 14.94 | 161.256B | ||
| SYK | STRYKER CORP | 21.26 | 126.004B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.81 | 89.097B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.39 | 48.118B | ||
| IDXX | IDEXX LABORATORIES INC | 38.38 | 45.663B | ||
| BDX | BECTON DICKINSON AND CO | 10.95 | 42.774B | ||
| RMD | RESMED INC | 17.69 | 32.344B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.26 | 32.159B | ||
| DXCM | DEXCOM INC | 23.33 | 23.634B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.76 | 17.923B | ||
| PODD | INSULET CORP | 28.2 | 13.042B | ||
| PEN | PENUMBRA INC | 63.95 | 12.896B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AXGN
Company Profile
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 622 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
Company Info
IPO: 1986-12-17
AXOGEN INC
13631 Progress Blvd., Suite 400
Alachua FLORIDA 32615 US
CEO: Karen Zaderej
Employees: 622
Phone: 13864626817
AXOGEN INC / AXGN FAQ
What does AXGN do?
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 622 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
What is the current price of AXGN stock?
The current stock price of AXGN is 41.99 USD. The price increased by 6.6% in the last trading session.
What is the dividend status of AXOGEN INC?
AXGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of AXGN stock?
AXGN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the GICS sector and industry of AXGN stock?
AXOGEN INC (AXGN) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Would investing in AXOGEN INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AXGN.
What is the ownership structure of AXOGEN INC (AXGN)?
You can find the ownership structure of AXOGEN INC (AXGN) on the Ownership tab.